



## CureDM, Inc.

### CureDM, Inc. Announces the Closing of a Series B Stock Placement

**Contact:** Donna Morrow  
[donna@curedm.com](mailto:donna@curedm.com)  
610.645.6796

**FOR IMMEDIATE RELEASE --Wynnewood, PA, November 30, 2006 ---** CureDM, Inc. announces the completion of their Series B private placement with two institutional investors. Scientific Health Development Partners led the round with Calvert Research Institute – a development and investment division of Calvert Holdings, Cary, NC. SHD Partners were keen to have participation by Calvert Holdings because they represent not only a capital partner, but also a key strategic partner in the preclinical plan for CureDM’s lead compound, Human proIslet Peptide. CureDM fits the profile of Calvert’s latest strategic initiative to invest in and operationally support young biopharmaceutical development companies with large market valuation potential.

“CureDM is an example of the type of company that will lead the future of medical innovations,” said Andy Burch, Vice President, Calvert Research Institute. “We believe that by investing in companies like Cure DM, and by using the drug development expertise of Calvert and its Research Institute partners, we are able to support development of new science initiatives faster and more efficiently. We believe there is a better way to help early stage companies bring their product leads to the market and we are trailblazing that path.”

The \$2.5 million Investment in CureDM, Inc. Series B Convertible Preferred Stock provides funds to advance the lead compound through pre-clinical stages toward the goal of IND status within the next twelve months.

#### **About CureDM**

CureDM, Inc., located on the Lankenau Institute for Medical Research campus in Wynnewood, Pennsylvania, and has an ongoing sponsored research agreement with the University of Pennsylvania Human Islet Laboratory. The company is developing a novel human peptide which stimulates the differentiation of adult pancreatic progenitor cells into insulin-producing islet structures providing a potential benefit to type 1 and type 2 diabetic patients. Calvert is currently conducting “proof of efficacy” studies in its Scranton, PA. laboratories. For more information about CureDM, visit [www.curedm.com](http://www.curedm.com).

#### **About Calvert Holdings**

Calvert Holdings is a privately held company consisting of several operating units competing in the healthcare services industry. Formed in 1996, management has focused the growth of the company on providing outsource drug development services to pharmaceutical and biotechnology companies. Through its Calvert Research Institute ([www.calvertresearchinstitute.com](http://www.calvertresearchinstitute.com)), the company has a very active program to evaluate early stage product leads for investment and in-licensing. For more information on Calvert Holdings, Inc., visit [www.calvertholdings.com](http://www.calvertholdings.com).

#### **About SHD, Partners**

Scientific Health Development, Ltd., (SHD), Dallas, Texas is a limited partnership that has been formed to identify, create, acquire, develop and monetize technologies, processes and companies in the health, science, medical and wellness industries. Prior to the formation of SHD, the Principals have made multiple and significant investments in the health, science, medical and wellness industries, such as the stent, which was named in 2002 by *IP Worldwide* as one of the “10 Patents that Changed the World”. Several of their investments have been purchased by major pharmaceutical and biotechnology companies such as Johnson & Johnson and St. Jude Medical.

**CUREDM, INC.**  
100 LANCASTER AVENUE, SUITE R215  
WYNNEWOOD, PA 19096  
PH: 610.645.6796  
WWW.CUREDM.COM